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Abstract:  
 
 Food and Drug Administration (FDA) and Centers for Medicare and Medicaid Services 
(CMS) rely on evidence from clinical trials when approving a therapeutic for marketing and 
insurance coverage in the US, respectively. No study has compared the quality and quantity of 
evidence examined by these agencies. Our purpose was to characterize evidence used by FDA 
and CMS to support marketing approval and coverage of novel therapeutics reviewed for CMS 
coverage from 2005 through 2016.We conducted a cross-sectional study of clinical trials 
described in FDA approval documents and CMS NCD memoranda. We compared the number of 
clinical trials used by each agency as well as the following characteristics of clinical trials: study 
size, randomization, double-blinding, and control arm. Twelve medical products met our 
inclusion criteria. FDA approvals were based on 22 pivotal trials. CMS NCDs were based on 27 
original clinical trials; 14 clinical trials were used by both agencies. Between FDA pivotal and 
CMS original clinical trials, there was no significant difference in study size (P = .53), use of 
randomization (P = .75), double-blinding (P = .55), or control arm (P = .54). There was no 
statistically significant difference in median age between participants in trials reviewed by CMS 
versus those reviewed by FDA (62 vs 59 years, P = .26). The median time from FDA approval to 
publication of CMS NCD memorandum was 17 (interquartile range, 13-36) months. FDA 
approvals and CMS NCDs are based on a similar number and quality of trials, although trial 
participants are not reflective of the Medicare population, and the process of finalizing coverage 
determinations requires an additional 17 months. 
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 1 
INTRODUCTION 
 
 Marketing approval for medical devices, drugs, and biologics in the United States is 
granted by the Food and Drug Administration (FDA). Following approval by the FDA, a product 
requires third-party payer coverage for clinical adoption; in the US, the largest third-party payer 
is the Centers for Medicare and Medicaid Services (CMS), with Medicare alone covering 56.8 
million Americans.(1) Both the FDA and the CMS rely on evidence from clinical trials when 
making their approval and coverage decisions, respectively. However, each agency has a specific 
goal in mind. The FDA must evaluate evidence to determine whether a product is “safe and 
effective”, whereas the CMS must use evidence to determine whether a product or procedure is 
“reasonable and necessary for the diagnosis or treatment of an illness or injury”.(2-4) Despite 
these overarching differences in the purpose of evidence review, we do not have a formal 
comparison on the type and quality of evidence reviewed by the FDA and the CMS to support 
their decisions. Characterizing clinical trial evidence used by the two agencies is therefore 
important for understanding how product approval and payer coverage processes are linked, and 
ultimately how millions of patients are able to receive beneficial medical treatment.  
 
Overview of the FDA Approval Process  
 
 The FDA, an agency within the U.S. Department of Health and Human Services, is 
responsible for protecting the public health by assuring the safety, quality, and security of human 
and veterinary drugs, vaccines and other biological products, and medical devices.(5) The FDA 
is also responsible for the safety and security of products such as cosmetics, dietary supplements 
and most of the U.S. food supply.(5) The agency is organized into four directorates and the 
Office of the Commissioner.(6) The four directorates include: Foods and Veterinary Medicine, 
Medical Products and Tobacco, Global Regulatory Operations, and Operations.(6) Within 
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Medical Products and Tobacco, the following divisions are responsible for approval of medical 
devices, drugs, and biologics, respectively: Center for Devices and Radiological Health (CDRH), 
Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and 
Research (CBER).(7) Details on the approval process for each type of medical product are 
outlined below.  
 
Medical Devices  
 
 In 1976, Congress granted the FDA the authority to regulate all medical devices.(8) This 
authority was bestowed following the Dalkon Shield intrauterine device controversy, whereby 
use of the device led to hundreds of septic spontaneous abortions and multiple maternal 
deaths.(8, 9) With this law, the premarket approval (PMA) application was instituted. The PMA 
application required clinical testing with scientific evidence that provided “reasonable assurance 
that they device [was] safe and effective for its intended use…in the target population”.(8, 10) 
Today, similar to initial requirements,  the PMA application is reserved for class III medical 
devices.(10) Class III devices are those products considered to carry the highest risk and that 
perform life sustaining or supporting functions and include prosthetic heart valves and coronary 
stents.(10) In brief, there are four steps necessary in order to review a PMA application: (1) an 
administrative and limited scientific review by FDA staff to determine completeness of the 
application; (2) an in-depth scientific, regulatory and quality system review; (3) a review and 
recommendation by the appropriate advisory committee; (4) final deliberations, documentation 
and notification the FDA decision.(11) Valid scientific evidence must be presented, mostly 
including randomized controlled trials and single-arm studies with historical controls; although 
case histories are sometimes included in the review.(10) Generally, the FDA prioritizes review of 
pivotal trials, or those clinical studies that “[gather] the final data on safety and effectiveness 
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needed for FDA review.”(12) 
 The FDA is required to complete its review of a PMA within 180 days of the 
manufacturer filing their application.(13) Once a PMA is approved, a summary of safety and 
effectiveness data (SSED) is available on-line to the public.(14) The goal of the SSED is to 
“summarize the key content of the PMA, such as Device Description, Preclinical Evidence, and 
Clinical Evidence, as well as FDA’s analysis of the scientific evidence that served as the basis 
for FDA’s [approval or non-approval] decision.”(15)  
 Following class III devices are moderate-risk or class II medical devices, with an 
intended use and safety profile similar to a predicate device.(10) Class II products, which in fact 
represent the majority of new medical devices, are approved through the 510(k) pathway.(10) 
Additional clinical data are usually not required if manufacturers can show “substantial 
equivalence” to a previously approved device.(16) Examples of moderate-risk devices include 
coronary guidewires, and contrast auto-injection systems.(10) The FDA provides a 510(k) 
summary on-line for class II medical devices, which includes information on the intended use of 
the product, and the technological characteristics of the device compared to a predicate device, 
along with additional legality data.(17)  
 Initially, there were numerous differences between the PMA and 510(k) approval 
process, including “limited authority for the FDA to withdraw clearance of a [moderate-risk] 
device that is found to be unsafe or ineffective” and lack of premarket inspections into device 
manufacturing.(8) Controversy arose when high-risk medical devices were approved using the 
510(k) pathway, without reassurance that clinical trial data supported safety and efficacy of the 
product.(8) In response, the FDA issued a report in 2010 stating that products in the 510(k) 
pathway should require data from clinical trials and that they should be subject to premarket 
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inspections and postmarket studies.(8) Since the report, changes have been made to increase 
postmarket surveillance and premarket inspection of moderate-risk devices; life-saving and 
sustaining products (i.e. high-risk devices) are subject to the specific PMA review process.(8) 
Lastly, class I devices (e.g. adhesive bandages and hearing aides) are considered low-risk and are 
“non-life sustaining with [a] long history of safety and effectiveness”.(10) Most class I devices 
do not require approval through the 510(k) pathway.(18)  
 
Drugs  
 The CDER is responsible for approving over-the-counter (OTC) and prescription 
drugs.(19) If a manufacturer wants to submit a new drug for approval, they must submit a new 
drug application (NDA), which must support the drug’s safety and effectiveness for its intended 
use.(20) In addition, manufacturers are required to report results of all clinical tests, the specific 
ingredients of the drug, results of animal studies, how the drug behaves physiologically, how it is 
manufactured and how it is processed and packaged.(20) Before an NDA is submitted however, 
the drug must go through preclinical phase testing.(21) The goal of preclinical phase testing is to 
use an animal model to achieve the desired clinical effect and ultimately predict outcomes of the 
treatment in humans.(22) A second goal of preclinical studies is to identify and characterize 
toxicities of the drug to predict adverse events in patients.(22) At this point, the manufacturer 
submits an investigational new drug (IND) application to the FDA and follows up with clinical 
trials.(22)  
 In general, clinical studies are classified as either Phase I, Phase II or Phase III.(23) Phase 
I trials provide information on a drug’s pharmacokinetic profile, side effects, tolerability, toxicity 
and dosing schedule; both Phase II and Phase III trials are designed to study the risks of benefits 
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of the drug and are much larger studies than Phase I trials.(23) Similar to the review process for 
medical devices, the FDA classifies certain studies as pivotal trials that are often used as the 
basis for the FDA’s approval decision.(3) In general, the FDA requires “adequate and well-
controlled investigations” and recommends that manufacturers submit data from at least two 
clinical trials.(3) Finally, an NDA is submitted to the FDA that contains results from all 
preclinical and clinical testing.(21) In general, the FDA is given a time period of 12-months to 
review an NDA and 6-months if an application falls under priority review (e.g. drugs that are 
considered to have significant advances over current therapies).(21) Once approved, drug 
approval summaries are made available on-line by the FDA.(24) These summaries contain 
comprehensive information on topics ranging from drug labeling, medical reviews, and 
pharmacology reviews. (24) However, it is important to note that any clinical trial data 
considered confidential or commercial may not be included for public review.(23) 
 
Biologics  
 Biologics are “active pharmaceutical ingredients derived from living organisms that 
cannot reasonably be synthesized by chemical means.”(25) Insulin, the first biologic medicine, 
was originally derived from extraction of the hormone from pancreatic tissue of cattle and 
pigs.(25) Later, insulin was produced using a recombinant DNA technology.(25) In brief, 
recombinant DNA technology involves synthesizing DNA fragments that contain a particular 
gene, inserting them into vectors, and inserting those vectors into a host organism such as a 
bacterium.(26) The hosts are then grown to produce multiple clones of the DNA fragment.(26) 
Today, there are several distinct classes of biologics including monoclonal antibodies (mAbs), 
receptor modulators, and enzyme modulators.(27)  
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 Monoclonal antibodies are monovalent antibodies that bind to the same antigen-binding 
site and are manufactured from a single clone of B-lymphocytes.(28) Examples include 
rituximab used for non-hodgkin’s lymphoma and infliximab for rheumatoid arthritis.(29, 30)  
Receptor modulators, such as tamoxifen for the prevention and treatment of breast cancer, bind 
to and affect a variety of receptor subtypes.(31) Enzyme modulators either induce or inhibit 
enzyme activity and include the drug alteplase, a potent thrombolytic.(27) 
 In order for a manufacturer to market their biologic, they must have an approved 
investigational new drug application, followed by adequate clinical trials and eventual 
submission of an NDA or Biologics License Application (BLA).(32) Like applications for 
devices and drugs, the FDA generally bases its approval decision on a few key pivotal trials. 
Following FDA approval, third-party payers such as CMS conduct their own review to determine 
whether a product should receive coverage. 
 
Overview of the Medicare Coverage Process 
 The majority of Medicare coverage decisions are made by contracted insurers at the state 
or region-wide level.(33, 34) These local insurers issue local medical review policies (LMRPs) 
that are only effective within their coverage area.(33) However, the central CMS agency will 
issue between ten to fifteen national coverage decisions (NCDs) per year for those products that 
are deemed particularly controversial or are projected to have a major impact on the Medicare 
program.(34) NCDs can be requested either by an outside organization or by CMS directly. CMS 
will generally make a request for an NCD under the circumstances such as: conflicting local 
coverage decisions, new evidence of a technology that promises large clinical impacts, or if there 
is significant uncertainty about a product’s risks and benefits.(34)  
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 The content of an NCD includes the final decision of CMS along with conditions for 
coverage if approved, background of the condition the product is intended to treat, history of 
Medicare coverage, timeline of activities leading to the coverage decision, FDA status of the 
product, a review of evidence used to support the final coverage decision, links to an external 
technology assessment if commissioned, results of an internal technology assessment, literature 
review, whether CMS requested a Medicare Evidence Development and Coverage Advisory 
Committee (MEDCAC) meeting, and results from that meeting if applicable.(35) Clinical 
guidelines, public comments, and professional society position statements may also be 
included.(35) In particular, MEDCAC statements and external technology assessments are 
unique aspects of the national CMS coverage review process.  
 The purpose of the MEDCAC is to “provide external assistance in judging the strength of 
evidence for NCDs”.(34) Their recommendations are used as a supplement and are often based 
on a review of medical literature, technology assessments, and public testimony.(36) The CMS 
selects up to 100 committee members from a wide range of backgrounds including patient 
advocacy and clinical and administrative medicine to serve on the MEDCAC.(36) For each 
meeting, a maximum of fifteen members with relevant experience are expected to provide 
recommendations on a specific product.(36) The CMS may also request an external technology 
assessment when, among other reasons, the total quantity of evidence to review is too extensive, 
the review requires unique technical or clinical expertise, or when the topic was referred to 
MEDCAC for additional recommendations.(37) The CMS will generally contract with the 
Agency for Healthcare Research and Quality (AHRQ) for an external technology assessment and 
the completed report includes a a summary of the literature search strategy, along with the final 
technology assessment.(37)  
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 NCDs can apply to medical devices, surgical procedures, diagnostic imaging, drugs, 
and/or drug delivery systems.(38) Furthermore, the final coverage decision can be one of the 
following: full coverage, coverage with restrictions, referral to local contractors, or noncoverage; 
once a decision is made, all local Medicare contractors are bound to that particular NCD.(38)  
 
Review of Relevant Policy Literature 
 There are several pertinent studies that have evaluated the strength of evidence reviewed 
by FDA and CMS independently. Downing et al. reviewed clinical trial evidence used to support 
FDA approval of novel therapeutics.(3) Similar to our study, they characterized pivotal trials 
used to support the final approval decision and evaluated implementation of randomization and 
blinding, features that are associated with higher-quality studies.(3) They also studied the type of 
comparator, clinical trial endpoint, trial duration and completion rate.(3) The quality of evidence 
used to support FDA approval varied widely across several indications; specifically, the choice 
of comparator and trial end point as well as the size and duration of trials varied greatly.(3) 
However, approval for each product indication was supported by at least one randomized 
controlled double-blinded trial.(3)  
 A study by Rathi et al. also evaluated clinical trial evidence supporting FDA approval of 
medical products, with a focus on otolaryngologic prescription drugs.(39) Similar to Downing’s 
study, the authors found that most product indications were supported by at least one randomized 
controlled study.(39) In addition, they found that almost half of indications were approved using 
studies that included a surrogate marker (e.g. “a biomarker expected to predict clinical benefit, 
such as progression-free survival”) as a primary endpoint.(39)  
 Rathi et al. also studied clinical trial evidence used to support FDA approval of high-risk 
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otolaryngology medical devices.(40) Results showed that fewer than half of trials used to support 
medical device approval were randomized, blinded or controlled.(40) Authors mentioned that in 
prior studies of cardiovascular, orthopedic, and neurosurgical devices, those products approved 
on the basis of limited evidence were more likely to be unsafe.(40-43) Another study by Hwang 
et al. evaluated pivotal clinical trials used to approve novel ophthalmic drugs and medical 
devices.(44) Over 90% of ophthalmic drugs were approved based on randomized and blinded 
trials; however, fewer trials used to support ophthalmic device approval were randomized 
compared to trials for ophthalmic drugs.(44) Several studies have also explored clinical evidence 
used to support Medicare NCDs; research published by Neumann et al. is particularly relevant.  
 In 2008, Neumann et al. published an analysis of Medicare NCDs issued from 1999 
through 2007.(34) For most NCDs, CMS considered the available supporting evidence to be 
either of fair or poor quality with higher strength of evidence for drugs than for other products, 
similar to results from Hwang et al.(34) Evidence was classified as “good” if trials were well-
designed and were conducted in representative populations.(34) Authors also studied mean CMS 
review time, with an average duration of 243±65 days from the date when a review was initiated 
by CMS to the date the final decision memorandum was published.(34) Results from a prior 
study by Neumann et al. examining NCDs published from 1998 to 2003 yielded similar 
conclusions; most often, technologies demonstrated a moderate net-benefit, but their evidence 
base was generally considered fair.(45) In some cases, there was insufficient evidence to 
determine whether there was a net-benefit.(45) However, in both studies, products with good 
evidentiary support were more likely to be covered.(34, 45) 
 Dhruva et al. focused on the generalizability of clinical data used to support NCDs to the 
Medicare beneficiary population.(14) Their meta-analysis of over 40,000 patients from 141 trials 
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showed that characteristics of trial patients differed markedly from the Medicare population; trial 
participants were more likely to be younger, male, and residents outside the U.S.(14) This is 
particulary concerning as the Medicare population is mostly female, and most are above 65 years 
of age (with the exception of qualifying patients <65 years of age); reported outcomes and 
adverse events of such high-risk cardiovascular devices may therefore not translate to the 
intended population.(14) Many of the findings from these aforementioned studies were the 
inspiration for this thesis research.  
 
Aligning FDA and CMS Requirements through Parallel Review   
 The FDA-CMS parallel review program was initially proposed in 2010 as a way to 
streamline the process from FDA approval to approval for CMS coverage.(46) In other words, 
product manufacturers who are planning to seek Medicare coverage for their technology could 
ask CMS to start the review time in conjunction with later stages of FDA review.(46) 
Furthermore, parallel review attempts to reconcile the goals of evidence review by the FDA and 
the CMS.(46) For example, clinical trials geared towards FDA approval are often based on rigid 
protocols with “narrow patient populations” that are designed to demonstrate a product’s safety 
and efficacy.(46) However, these populations are often not reflective of real-world patients. On 
the other hand, the CMS requires evidence that will help them determine whether or not the 
product will be reasonable and necessary for the broader population of Medicare 
beneficiaries.(46) Therefore, the parallel review program has the potential to both fast-track the 
adoption of beneficial technologies for Medicare beneficiaries, and to significantly improve the 
evidence base upon which approval and coverage decisions are made.  
 One such success example of the parallel review program is the diagnostic test 
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Cologuard. In brief, cologuard is used as a stool DNA screening test to detect biomarkers 
associated with colon cancer.(47) In a multi-center cross-sectional study, cologuard detected 
69.2% of advanced pre-cancerous lesions compared with 46.2% lesion detection with the fecal 
occult blood test FIT.(48) Through the parallel review pathway, time from PMA submission to 
the FDA to publication of the final CMS NCD was 489 days compared with 612 days for similar 
products going through the standard FDA approval and CMS coverage process.(47) Therefore, 
coverage and reimbursement for Cologuard was available much sooner for Medicare 
beneficiaries than it would have been without the parallel review program. Parallel review was 
eventually made permanent in 2016, although it is currently restricted to medical devices.(49)  
 
STATEMENT OF PURPOSE 
 The purpose of this study was to address a major gap in our understanding of how the 
FDA and the CMS, two of the most influential regulatory agencies for healthcare in the U.S., 
compare in their use of evidence to approve and cover medical products that will ultimately be 
used by millions of Medicare beneficiaries. To achieve this, we characterized evidence used to 
support both FDA approval decisions and CMS coverage decisions for novel medical products, 
including medical devices, drugs, and biologics. More specifically, we analyzed the proportion 
of clinical trials that had the following characteristics associated with good-quality evidence: use 
of randomization, blinding, inclusion of a control group, inclusion of either a placebo or active 
comparator, and use of a clinical outcome as a primary measure of efficacy. Then we compared 
clinical trial characteristics between the two agencies to evaluate whether there were any 
discrepancies in the type, quality, and number of clinical trials used to approve and cover a 
medical product.  
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 In addition, we examined the length of time from FDA approval to initiation of an NCD 
and the time from FDA approval to publication of the final NCD. This was important for us to 
point out in our study as delays in time from FDA approval to NCD initiation and publication 
ultimately delay availability of innovative medical technology. Lastly, we described trial 
participant age and gender for all original trials reviewed in the CMS coverage review process, 
and analyzed results in the context of average age and gender of Medicare beneficiaries. Given 
that prior studies have shown that CMS relies mostly on fair to poor quality evidence for review, 
and that the demographic of trial participants was found to be inconsistent with that of the 
intended Medicare population, we hypothesized that clinical trials evaluated by the FDA will be 
more robust than trials evaluated by the CMS. We further hypothesized that neither patients in 
trials evaluated by the FDA nor patients in trials evaluated by the CMS would be reflective of 
Medicare beneficiaries.  
 
METHODS 
 
Identifying CMS NCDs and FDA Approval Documents 
 The Medicare Coverage Database (https://www.cms.gov/medi care-coverage-database/) 
offers public access to local and NCD memoranda and other documents germane to the Medicare 
coverage determination process. NCDs are published memoranda that include the following 
information: the coverage decision (covered, covered with evidence development, or not 
covered), a concise background of the disease intended to be diagnosed or treated, the history of 
Medicare coverage, a timeline of recent activities, FDA status of the medical product, general 
principles of Medicare’s evidence review, the evidence base evaluated by CMS through both 
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internal and external technology assessments, reports of MEDCAC meetings, and professional 
society position statements or guidelines that informed the final coverage decision. In December 
2016 and January 2017 we downloaded all NCD memoranda and external technology 
assessments referenced in the memoranda.  
 All FDA approval documents were available on-line. For moderate-risk devices, 510(k) 
summaries were downloaded from the FDA website. Links to FDA Summaries of Safety and 
Effectiveness Data (SSEDs) for all high-risk medical devices were included in the corresponding 
Medicare determination memoranda. The SSED is a document whose goal is to provide a 
reasoned, objective, and balanced critique of the scientific evidence which served as the basis of 
the decision to approve or deny the premarket approval (PMA) [application].(15) Approval of a 
PMA application is based on a determination by FDA that the PMA contains sufficient valid 
scientific evidence to assure that [a high-risk device] is safe and effective for its intended 
use(s).(15) Approval documents for pharmaceuticals and biologics were obtained through the 
Drugs@FDA on-line database and the FDA site for approved products under Vaccines, Blood, 
and Biologics, respectively, in December 2016 and January 2017.  
 
Selection of Final Study Sample  
 We included all NCD memoranda published from January 1, 2005, through December 
31, 2016, that pertained to high-risk medical devices, moderate-risk medical devices, 
pharmaceuticals, or biologics, including both NCDs that resulted in coverage and those that did 
not. We excluded NCDs for diagnostic technologies, non-medical services, or surgical 
procedures that did not include discussion of a specific therapeutic product (Figure 1).  
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Identification of Original Clinical Trials Review by CMS 
 
 Each NCD was reviewed by 1 investigator (ACR) who identified original clinical trials 
used by CMS to support its NCD. Included trial evidence was summarized within the 
memoranda under the ‘Internal Technology Assessment’ section, which summarizes CMS’ 
evidence assessment. Original trials (e.g., excluding follow- up studies, interim-analyses, and 
pooled studies) reviewed by CMS were compared with pivotal trials used to support FDA 
approval. Uncertainty about trial inclusion was resolved by consensus between 2 investigators 
(ACR and JSR). We also recorded those additional studies that were based either on the original 
clinical trials reviewed by CMS or on FDA pivotal trials. These studies were not included in the 
sample of original clinical trials and included follow-up studies, pooled analyses, or interim 
analyses.  
Figure 1. Selection of NCDs issued by 
Medicare from 2005 through 2016, covering 
medical devices, drugs, and biologics. 
*These products were listed in the context of a 
therapeutic procedure, but were not the focus of 
the NCD.  
NCD = National Coverage Determination 
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Identification of FDA Pivotal Efficacy Trials 
 One investigator (ACR) identified trials labeled “pivotal” or “primary efficacy and 
safety” in FDA Medical Reviews for each included pharmaceutical or biologic and in SSEDs for 
high-risk devices. Of note, some pivotal trials in SSEDs were identified with a preceding 
statement such as “data from these clinical studies were the basis of the PMA approval decision.” 
Trials with narrative summaries within 510(k) documents for moderate-risk devices were 
classified as pivotal trials. Any uncertainty on identification of a pivotal trial was resolved by 
consensus among all study investigators.  
 
Data Extraction  
 For each NCD, the following data were extracted from the decision memorandum: date 
of NCD initiation, date of NCD posting by CMS, individual or agency requesting the NCD, 
number and type of products specified for coverage, whether MEDCAC was convened, whether 
an external technology assessment was requested (either from the Agency for Healthcare 
Research and Quality [AHRQ] or another external health technology assessment body), whether 
the referenced external technology assessment discussed cost-effectiveness, and the final 
coverage decision (covered, covered with evidence development [CED], or not covered). Links 
to NCD decision memoranda are provided on the CMS website for each NCD. The FDA 
approval date was determined from the NCD decision memoranda or from primary FDA 
approval documents.  
 We collected the following data to characterize all original trials evaluated by CMS and 
FDA: study size, use of randomization, use of double-blinding, inclusion of a control arm 
(placebo or active control), age of trial participants, proportion of female trial participants, 
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proportion of trials incorporating clinical outcome(s) as a primary efficacy measure, proportion 
of trials including a US study location, and proportion of trials with multiple enrollment sites. 
Four of these variables (study size, use of randomization, double-blinding, and inclusion of a 
control arm) were considered primary trial characteristics based on the Cochrane Study Quality 
Guide and prior studies examining quality of evidence reviewed in CMS NCDs.(34, 45, 50) 
 
Statistical Analysis  
Characterization of NCDs  
 Descriptive statistics were used to evaluate mean CMS review time (from initiation of 
NCD request to publication of decision memorandum); proportion of NCDs initiated internally 
by CMS; proportion of memoranda that referenced an advisory report from MEDCAC; 
proportion of memoranda that referenced an external technology assessment; proportion of 
external technology assessments that included a discussion of cost-effectiveness; median number 
of public comments in each of the 2 public comment periods (an initial 30-day period after 
initiation of the NCD request, and a second 30-day period after publication of the proposed 
decision memorandum); and proportion of NCDs referencing profession- al society statements, 
clinical practice guidelines, FDA approval documents, or expert opinion. We also determined the 
proportion of CMS evaluations leading to a positive coverage decision, including CED. All 
calculations were performed in Microsoft Excel v. 15.31 by 1 investigator (ACR) with 
verification by JSR and SSD.  
 
Characterization of trials evaluated by FDA and CMS 
 For original clinical trials, we used descriptive statistics to evaluate the aforementioned 
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trial characteristics. The proportion of secondary analyses (i.e., interim-studies, follow-up 
analyses, pooled studies) reporting data on patients with an average age of at least 65 years was 
also determined. We used the Fisher Exact Test to compare the following characteristics among 
trials reviewed by FDA and CMS: use of randomization; double- blinding; inclusion of a control 
arm (active or placebo); inclusion of a US study location; enrollment from multiple study sites; 
and inclusion of a clinical outcome in primary efficacy analyses. The Wilcoxon Signed-Rank 
Test for paired samples was used to compare the total number of trials evaluated by each agency, 
the age of participants across original trials, the proportion of female trial participants, and the 
sample size across original clinical trials. Of note, the proportion of female trial participants was 
only evaluated for 10 of the 12 products because 2 products pertained to the treatment of prostate 
cancer (PROVENGE and Plenaxis). All tests were 2-tailed and used a type I error rate of 0.05. 
Analyses were conducted using Excel v. 15.31 by 1 investigator (ACR.), with subsequent 
verification by JSR and SSD. Because this study made use of publicly-available documents and 
materials and did not use human subject data, it was exempt from review by the Yale 
Institutional Review Board.  
 
RESULTS 
Characteristics of NCDs  
 From 2005 through 2016, 11 CMS NCDs covering 12 products (1 NCD included 
coverage for 2 FDA approved products) met our inclusion criteria. These included 3 
pharmaceuticals, 1 biologic, 6 high-risk medical devices, and 2 moderate-risk devices. CMS 
initiated 4 NCD requests, 3 were requested by product manufacturers, 2 by medical societies, 1 
by a Medicare beneficiary, and 1 by a physician.  
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 Median CMS review time was 263 (IQR, 248–272) days. Only 1 (9.1%) NCD included 
MEDCAC review. Five (45%) NCDs reviewed an external technology assessment, 2 of which 
included information on cost-effectiveness (Table 1). Eight (73%) NCDs considered professional 
society statements, and 7 (64%) referenced clinical practice guidelines. Nine (82%) NCDs 
specifically stated that FDA approval documents were taken into consideration during the 
coverage determination process. Six NCDs (54%) referenced expert opinion.  
 The median number of public comments during the first period for all NCDs was 43 
(IQR 19-139), and for the second comment period was 76 (IQR 38-164).  
 A total of 8 (73%) NCDs were positive coverage determinations, with 3 (38%) of those 
requiring coverage with evidence development. The remaining 3 NCDs were determinations by 
CMS to not provide coverage.  
 
Number of Trials Evaluated by the FDA and CMS  
 CMS NCDs for the 12 medical products were based on 27 original clinical trials, and 11 
secondary analyses of the original clinical trials. FDA approval of these same 12 products was 
based on review of 22 pivotal trials. Fourteen (52%) of the 27 original clinical trials evaluated by 
CMS were the same pivotal trials examined by the FDA (Table 1). Eight (4%) of the pivotal 
trials evaluated by FDA were not included in CMS NCDs. Of these 8 trials, 4 were for a 
pharmaceutical (Natrecor), 3 for 1 high-risk medical device (SCULPTRA), and 1 for a different 
high-risk medical device (MitraClip). The NCD for Natrecor did include a brief result summary 
from the FDA pivotal trials, along with reference to a meta-analysis that included data from 
clinical trials used to support FDA approval. The NCD for dermal injections of facial 
lipodystrophy syndrome, which included SCULPTRA, included results from a 24-month 
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extension of 1 of the original FDA pivotal trials. Of the remaining 2 trials supporting 
SCULPTRA’s FDA approval, 1 was a randomized, controlled trial conducted in the US and the 
other was a single-arm trial conducted in the UK. Neither was specifically mentioned in the CMS 
NCD. The NCD for transcatheter mitral valve repair (MitraClip) includes a discussion of the 
FDA pivotal trial in CMS’ internal technology assessment.  
 There was no significant difference in the median number of clinical trials evaluated by 
the FDA and CMS for all products (FDA 1 [IQR, 1-2] versus CMS 2 [IQR, 1-2]; P = .59).  
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Table 1. C
haracteristics of trials used by the FD
A
 for approval decisions and C
M
S for national coverage determ
inations 
CM
S=Centers for M
edicare and M
edicaid Services, FDA=Food and Drug Administration, NCD=national coverage determination. *External technology assessment includes a 
discussion on cost-effectiveness. ∫ M
edian time elapsed from FDA approval to CM
S coverage (years) with interquartile range.  † NCD request generated before FDA was 
granted for the Edwards SAPIEN Heart Valve. This was highlighted in the NCD request. ‡ The Society of Thoracic Surgeons (STS), the American College of Cardiology 
Foundation (ACCF), the Society for Cardiovascular Angiography and Interventions (SCAI), and the American Association for Thoracic Surgery (AATS).  
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Characteristics of Trials Evaluated by the FDA and CMS  
 There were no significant differences in the characteristics of trials used to support FDA 
approval and CMS NCDs. Specifically, the following characteristics in original and pivotal 
clinical trials were similar in both groups: randomization (FDA: 15/22 [68%] versus CMS: 20/27 
[74%]; P = .75), use of either placebo or active control (FDA 14/22 [64%] versus CMS: 20/27 
[74%]; P=.54), double-blinding (FDA: 6/22 [27%] versus CMS: 10/27 [37%]; P = .55), and 
median number of enrolled study participants (FDA: 279 [IQR, 120–345] versus CMS: 291 
[IQR, 174–328]; P = .53) (Table 2).  
 The number of CMS clinical trials including a US study location was approximately 
equal to the number of FDA clinical trials including a US study location (FDA: 18/19 [95%] 
versus CMS: 22/27 [81%]; P = .63). Of note, study location was unavailable for 3 FDA pivotal 
trials. There was no significant difference in the number of multi-center clinical trials evaluated 
by FDA and CMS (FDA: 17/22 [77%] versus CMS: 22/27 [81%]; P = .74). There was no 
significant difference in the use of a clinical outcome measure as a primary efficacy endpoint 
(FDA: 18/22 [82%] versus CMS: 22/27 [81%]; P=1.00).  
 There was no significant difference in overall trial participant age (FDA: 59 years [IQR, 
45–73] versus CMS: 62 years [IQR, 48–72]; P = .26). Of the original clinical trials reviewed by 
CMS, 4 (15%) included a subgroup analysis for patients older than 65 years of age. Of the 11 
secondary analyses reviewed by CMS based on the original trials, 4 (36%) included subgroup 
data on patients older than 65 years. There was no significant difference in the proportion of 
female participants in FDA and CMS clinical trials (FDA: 29% [IQR, 20–44] versus CMS: 32% 
[24–29]; P= 1.00).  
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Table 2. C
om
parison of trial design betw
een the FD
A
 and C
M
S. 
CM
S=Centers for M
edicare and M
edicaid Services, FDA=Food and Drug Administration.   
*Based on one trial. † Interquartile range. ‡ Sample size reported as median value averaged over all original clinical trials. x CM
S original trials 
are the same as FDA pivotal trials.  
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Time from FDA Approval Initiation and Publication of a CMS NCD  
 The median time from FDA approval to initiation of an NCD was 9 (IQR, 4–29) months. 
The median time from FDA approval to publication of a CMS NCD memorandum was 17 (IQR, 
13–36) months.  
 
DISCUSSION 
Summary of Findings  
 We characterized clinical trials used to support FDA approval and CMS NCDs for novel 
medical products (pharmaceuticals, biologics, moderate and high-risk medical devices) that were 
issued NCDs from 2005 through 2016, focusing on characteristics reflective of high-quality 
evidence.(50)  There were no significant differences in use of randomization, double-blinding, 
control arm, or study size between original clinical trials evaluated by CMS and pivotal trials 
reviewed by FDA. Over half of original clinical trials reviewed by CMS were the same pivotal 
trials evaluated by FDA.  
 Participant demographics in trials reviewed by FDA and CMS were similar. Females 
constituted fewer than 50% of CMS trial participants, which is not significantly different from 
the median percent of female participants in FDA pivotal trials. In addition, neither CMS nor 
FDA trials had a median participant age above 65 years. However, CMS did include additional 
studies in its evaluation that frequently incorporated sub-group analyses of the original clinical 
trials for patients older than 65 years. 
 
Study Limitations 
 Limitations of our study include a small number of total reviewed NCDs; only 10 to 15 
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are issued annually by CMS, (34) whereas the majority of coverage decisions are made by 
regional contractors, whose determinations are not made publicly available. Such a small sample 
size of NCDs possibly did not give us the statistical power to detect differences between trial 
characteristics in studies evaluated by FDA and CMS. However, since NCDs are issued for the 
most controversial technologies likely to have a significant impact on the Medicare population 
and apply to all contractors, they are among the most important to study. We should note that the 
recently enacted 21st Century Cures Act institutes new requirements mandating greater 
transparency of these regional coverage decisions, including public availability of documents 
summarizing evidence that supported development of a local coverage determination.(51) As 
local coverage determinations become available, it would be useful to compare and contrast 
evidence used to support local versus national coverage determinations. In addition, it would be 
interesting for future researchers to gather additional data from NCDs as they accrue overtime 
and conduct additional subgroup analyses on trial characteristics, such as time of follow-up and 
use of an active or placebo comparison group. 
 Another potential limitation of our study is our focus on comparing pivotal clinical trials 
used to support FDA approval of a medical product, to original trials evaluated by CMS for 
product coverage. CMS often included multiple other studies in their review, ranging from 
systematic reviews and meta-analyses to case reports. There was no information in the NCD 
memoranda that definitively stated the value of each study to their review process. We can say 
that CMS was likely to prioritize original clinical trials, as these trials generally had qualities 
associated with a stronger evidence base (e.g randomization and blinding, as outlined in the NCD 
memoranda). The strength of evidence is important in the CMS coverage evaluation process, and 
it was our prediction that original clinical trials were nearly equivalent to FDA pivotal clinical 
 25 
trials. However, future research may benefit from a more comprehensive review of all CMS 
studies.  
 Additionally, CMS and FDA documents occasionally had missing data. For example, 
information on study site was unavailable for 3 FDA pivotal trials. This may have prevented us 
from making accurate conclusions on differences in trial location, although this was not a main 
outcome measure in our study.  
 
Implications for Regulatory Policy  
 Our finding that clinical trial characteristics are similar between the two agencies is of 
particular interest given differences in mandates for FDA approval and CMS coverage. FDA’s 
goal is to ensure that pivotal trials demonstrate safety and efficacy of the medical product, 
whereas CMS must ensure that trials show that a product is reasonable and necessary for 
diagnosis or treatment of an illness or injury in the Medicare population.(52) It is, therefore, 
reasonable to expect differences in trial characteristics. For example, FDA might be more likely 
to rely on a greater proportion of randomized, double-blind, placebo-controlled trials. CMS 
would be expected to prioritize trials that generalize to Medicare beneficiaries, including larger 
proportions of female participants over 65 years of age and that utilize active controls to 
determine if there is a benefit to covering the newer therapeutic over available alternatives. 
However, our results show that FDA and CMS not only rely on many of the same trials but even 
when other clinical trials are considered in Medicare’s review, there is no overall difference in 
the quality of trials evaluated by each agency. Variation in the objectives of evidence review by 
FDA and CMS does not reflect variation in the trials—and their characteristics—evaluated of 
product approval/ coverage.  
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 Regarding demographics of trial participants, our finding that the median age of patients 
was under 65 for studies reviewed by both agencies was concerning, along with our finding that 
approximately two-thirds of trial participants were male. This may have a significant impact for 
regulatory policy going forward, as more than half (54%) of Medicare beneficiaries are women. 
(53) and are greater than 65 years-of-age. These findings call into question the generalizability of 
those studies that are crucial for FDA approval and CMS coverage. In the future, it may become 
necessary for both agencies to seriously consider instituting requirements for manufacturers that 
they submit trials that are reflective of the Medicare population, particiulatly if those 
manufacturers are later seeking CMS coverage. Poor generalizability leads to poor external 
validity, which means that outcomes reported in clinical trials may not necessarily be reflective 
of real-world outcomes once the device is used in its intended patient population. We should note 
that there were several sub-analyses of patients older than 65-years-of-age among CMS original 
trials; however, this is not ideal and should not be used to replace high-quality studies that can be 
designed with the Medicare population in mind from trial initiation. Knowing the data 
specifications requested by CMS in advance (e.g median age of trial particpants should be >65 
years, and >50% should be female) might potentially help reduce the time lag from FDA 
approval to NCD initiation. This would be of great interet for future studies as more products are 
routed throught he parallel review program that was initially piloted and established for medical 
devices in 2016. (54) 
 Parallel review is an FDA–CMS collaboration designed to reduce the time between FDA 
review and CMS evaluation and to help manufacturers understand and address the data 
requirements of both agencies. (52)  Through the program, manufacturers can request initiation 
of a CMS NCD while the product is still under FDA review. (52) For example, CMS initiated 
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their coverage review for the Edwards SAPIEN transcatheter heart valve more than 1 month 
(9/28/11) before FDA approved the device (11/02/ 11). Whereas the SAPIEN transcatheter heart 
valve was not officially part of the parallel review program, this was 1 instance in which the 
manufacturer engaged both FDA and CMS before starting its pivotal clinical trial.(55)  Early 
review obviated the median 9-month delay from FDA approval to initiation of a CMS NCD that 
we found. Therefore, parallel review may substantially decrease the delay in FDA approval to 
CMS coverage for medical devices. Yet parallel review is only instituted for medical devices at 
this time and does not apply to drugs or biologics.  
 One possible reason for the lack of expansion of the parallel review program is that CMS 
issues so few NCDs for drugs and biologics that, presumably, incorporating these products into 
the parallel review pathways is unlikely to have a significant impact.(56) Futhermore, the 
pharmaceutical industry is not necessarily interested in purusing a parallel review track. (56) 
These are only two reasons as to why the parallel review program has not fully taken off even 
though the first pilot program was initiated over 8 years ago. Additional reasons include limited 
scope of the parallel review program; currently, the pathway is only for medical devices that 
require pre-market approval or must be approved under a de novo classification, meaning that it 
cannot be approved through the 510(k) pathway. (57) This requirement severely limits the 
number of medical products that are eligible for route through the parallel review program. For 
example, in 2014 there were over 3,000 510(k) device approvals through the FDA compared to 
only 42 PMAs. (57) Furthermore, if a manufacturer wants to go through the parallel review 
program, they are required to submit their product for approval through an NCD and if that 
product is not approved through an NCD, it will not be available for coverage anywhere in the 
U.S. through any regional contractor. (57) As a final comment, there is also a limit of how many 
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products can go through the parallel review pathway each year, (57) effectively creating a 
bottleneck for manufacturers who despite several limitations, may still want to pursue the 
parallel review program.  
 Possible ways to improve the parallel review program are first to expand inclusion 
criteria to include drugs and biologics, along with moderate-risk medical devices. Given that 
most Medicare coverage decisions are made by local contractors, it would also be prudent for 
CMS to expand the parallel review program to cover LCDs in addition to NCDs. Our study has 
shown that there is poor external validity in studies used to support FDA approval and CMS 
coverage, leading us to suggest that manufacturers could benefit considerably from greater 
involvement in a parallel review program that focuses on evaluation of studies that are 
generalizable to Medicare beneficiaries. However, other factors must be considered as well when 
merging FDA and CMS review processes.  
 CMS, unlike FDA, holds 2 30-day public comment periods for each NCD and its 
decision memorandum includes a summary of, and response to, comments received. Public 
comments are designed to enhance the “quality of agency decision making” and can encompass 
contributions ranging from medical society recommendations to patient narratives.(58) In order 
to streamline the parallel review program, perhaps the public comment period could be initiated 
within a specified time period following FDA approval.  
  Furthermore, CMS considers evidence-based guidelines and the opinions of members of 
the medical or scientific community (labeled “expert opinion” in NCD memoranda) and may 
consider MEDCAC reports. Since many of these additional reports and guidelines reflect direct 
patient and physician experiences with the medical product once it is on the market, it will be 
difficult to merge these processes through parallel review. An additional barrier to the parallel 
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review program may involve the relationship between manufacturers and the national CMS 
agency. Because of specific requirements for CPT coding, manufacturers may receive lower 
reimbursement rates from CMS once an NCD is issued. In addition, anecdotally, it has been 
suggested that manufacturers may have the potential to exert more influence in the local 
coverage determination (LCD) process, although this has not been systematically studied. 
 Despite these limitations, expansion of the parallel review program would be ideal for 
expediting the coverage process for beneficial medical devices, drugs and biologics. However, 
several limitations must first be addressed and manufacturers should be given more incentives 
for participating in the program.  
 
Conclusions  
 In conclusion, FDA approval and CMS NCDs of novel therapeutics often rely on the 
same clinical trial evidence and on trials of similar quality. However, the process of finalizing 
coverage determination requires an additional 17 months. FDA and CMS should continue to 
work together to ensure timely coverage decisions after FDA approval, perhaps by encouraging 
manufacturers to include larger proportions of older and female participants in their trials 
supporting FDA approval.  
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